AstraZeneca at SLAS2027
Jan 30 – Feb 3, 2027 San Diego, CA ~7.6k attendees Website
AstraZeneca brings 7 presentations to SLAS2027 in San Diego. Its program runs from short courses on genome editing, mass spectrometry and DMTA cycle automation to podium sessions on phenotypic screening and emerging assay technology. Its scientists also join the encoded libraries and biophysical lead discovery interest group.
| Organization | SLAS2027 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Biopharmaceutical company developing medicines in oncology, rare disease, cardiovascular, renal, metabolic and respiratory disease. | Workshop Sat Jan 30 8:30am–4:30pm Genome Editing and AI-Driven Approaches in Drug Discovery and Target Validation Workshop Sun Jan 31 8:30am–12pm Operationalizing DMTA: From Implementation to Continuous Optimization Workshop Sun Jan 31 8:30am–4:30pm An Introduction to Mass Spectrometry and its Applications within Drug Discovery Session Mon Feb 1 10am–12pm Advanced Imaging & Phenotypic Screening
Talk Mon Feb 1 10:30–10:55am Phenotypic profiling reveals targets impacting mitochondrial dysfunction in COPD Session Mon Feb 1 2–2:45pm Encoded Libraries and Biophyscial Lead Discovery Session Tue Feb 2 3–5pm Emerging Assays and Screening Technology Also |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with the Society for Laboratory Automation and Screening. Organization details are derived from SLAS’s published exhibitor list and event scheduler. Submit a correction